The phase 2a pilot study with 118 patients with mild or moderate ulcerative colitis, receiving 75 mg ST-0529 once daily, showed a numerically higher but not statistically significant difference in remission rate compared with placebo (13.2% vs 6.3%, P=0.22) after 4 weeks of treatment. Rates of clinical response were 30.2% and 18.8% (P=0.19). No differences were observed between the treatment groups for mucosal and histological healing. In the post hoc analysis, differences in the clinical response between treatment subgroups achieved statistical significance in some subgroups, with the largest clinical response rate seen in moderate ulcerative colitis patients taking 5-aminosalicylates and/or steroids. These preliminary data support further development of ST-0529 as a treatment for the induction and maintenance of remission in ulcerative colitis patients with moderate to severe disease.
- Bloom S, et al. ECCO 2019, OP16.
Posted on
Previous Article
« Network analysis of GWAS Next Article
ABX464: HIV drug tested in ulcerative colitis »
« Network analysis of GWAS Next Article
ABX464: HIV drug tested in ulcerative colitis »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
IBD risk of treatment with IL-17 antagonists
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com